
Safety Assessment of Starch Phosphates as Used in Cosmetics

Status: Tentative Report for Public Comment
Release Date: April 15, 2022
Panel Meeting Date: June 16-17, 2022

All interested persons are provided 60 days from the above release date (i.e., June 14, 2022) to comment on this safety assessment, and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to the Cosmetic Ingredient Review (CIR) will be discussed in open meetings, will be available for review by any interested party, and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Executive Director, Dr. Bart Heldreth.

The Expert Panel for Cosmetic Ingredient Safety members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; David E. Cohen, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The Cosmetic Ingredient Review (CIR) Executive Director is Bart Heldreth, Ph.D. This report was prepared by Wilbur Johnson, former Senior Scientific Analyst/Writer, and Regina Tucker, Scientific Analyst/Writer, CIR.

© Cosmetic Ingredient Review

1620 L Street, NW, Suite 1200 ♦ Washington, DC 20036-4702 ♦ ph 202.331.0651 ♦ fax 202.331.0088 ♦
cirinfo@cir-safety.org

ABBREVIATIONS

aq.	aqueous
ADP	adenosine diphosphate
ATP	adenosine triphosphate
CFR	Code of Federal Regulations
CIR	Cosmetic Ingredient Review
CPSC	Consumer Product Safety Commission
Council	Personal Care Products Council
EFSA	European Food Safety Authority
FAO	Food and Agriculture Organization
FDA	Food and Drug Administration
FDRL	Food and Drug Research Laboratories
HRIPT	human repeated insult patch test
JECFA	Joint FAO/WHO Expert Committee on Food Additives
LD ₅₀	lethal dose, 50%
OECD	Organisation for Economic Co-operation and Development
Panel	Expert Panel for Cosmetic Ingredient Safety
QSAR	quantitative structure-activity relationship
SIOPT	single insult occlusive patch test
SLS	sodium lauryl sulfate
SPF	specific-pathogen-free
US	United States
VCRP	Voluntary Cosmetic Registration Program
WHO	World Health Organization
wINCI	web-based <i>International Cosmetic Ingredient Dictionary and Handbook</i>

ABSTRACT

The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 4 starch phosphates as used in cosmetic formulations. Distarch Phosphate is reported to function in cosmetics as an anticaking agent and binder. Distarch Phosphate Acetate, Hydroxypropyl Starch Phosphate, and Sodium Hydroxypropyl Starch Phosphate are all reported to function as viscosity increasing agents. The Panel considered the available data, and concluded that these ingredients are safe in cosmetics in the present practices of use and concentrations described in this safety assessment.

INTRODUCTION

The safety of the following 4 starch phosphates as used in cosmetics is reviewed in this safety assessment.

Distarch Phosphate
Distarch Phosphate Acetate

Hydroxypropyl Starch Phosphate
Sodium Hydroxypropyl Starch Phosphate

According to the web-based *International Cosmetic Ingredient Dictionary and Handbook* (wINCI; *Dictionary*), Distarch Phosphate is reported to function in cosmetics as an anticaking agent and a binder (Table 1).¹ Distarch Phosphate Acetate, Hydroxypropyl Starch Phosphate, and Sodium Hydroxypropyl Starch Phosphate have several reported functions, but all 3 are reported to function as viscosity increasing agents.

All of the ingredients reviewed in this safety assessment may be consumed in food, and daily exposure from food use would result in much larger systemic exposures than those from use in cosmetic products. Therefore, although oral studies are included in the document, the primary focus of the safety assessment is on the potential for local effects from topical exposure to these ingredients as used in cosmetics.

Some starch ingredients derived from a specific species (e.g., *oryza sativa* (rice) starch,² *zea mays* (corn) starch,³ and *triticum vulgare* (wheat) starch⁴) have previously been reviewed by the Expert Panel for Cosmetic Ingredient Safety (Panel). These ingredients were found safe as used as described in the report.

This safety assessment includes relevant published and unpublished data that are available for each endpoint that is evaluated. Published data are identified by conducting an exhaustive search of the world's literature. A list of the typical search engines and websites that are used and the sources that are typically explored, as well as the endpoints that the Panel typically evaluates, is provided on the Cosmetic Ingredient Review (CIR) website (<https://www.cir-safety.org/supplementaldoc/preliminary-search-engines-and-websites>; <https://www.cir-safety.org/supplementaldoc/cir-report-format-outline>). Unpublished data are provided by the cosmetics industry, as well as by other interested parties.

Much of the data included in this safety assessment were found in reports by the Joint Food and Agriculture Organization (FAO)/World Health Organization (WHO) Expert Committee on Food Additives (JECFA).⁵⁻⁷ Similarly, data from a report by the European Food Safety Authority (EFSA) Panel on Food Additives and Nutrient Sources are also included.⁸ Please note that these reports provide summaries of information from other sources, and it is those summary data that are included in this safety assessment when JECFA or EFSA are cited.

CHEMISTRY

Definition

According to the *Dictionary*, Distarch Phosphate (CAS No. 55963-33-2) is defined as the product resulting from the cross-linking of starch with sodium metaphosphate, and its acetate form, Distarch Phosphate Acetate (68130-14-3), is the product of Distarch Phosphate and acetic anhydride (Table 1).¹ Hydroxypropyl Starch Phosphate (CAS Nos. 113894-92-1, 39346-84-4, and 53124-00-8) is an ether, and Sodium Hydroxypropyl Starch Phosphate (CAS No. 221355-22-2) is the sodium salt of that ether.

Modified food starches are defined in the *Food Chemicals Codex* as products of the treatment of any of several grain- or root-based native starches (for example, corn, sorghum, wheat, potato, tapioca, and sago) with small amounts of certain chemical agents that modify the physical characteristics of the native starches to produce desirable properties.⁹ Starch is composed of two kinds of polysaccharides, amylose and amylopectin,¹⁰ and it is comprised of α -1,4 and α -1,6 linked glucose.¹¹ According to the *Food Chemicals Codex*, starch molecules are polymers of anhydroglucose and exist in both linear and branched form. The degree of polymerization and the molecular weight of the naturally-occurring starch molecules vary radically. Additionally, they vary in the ratio of branched-chain polymers (amylopectin) to linear-chain polymers (amylose), both within a given type of starch and from one type to another. These factors significantly affect the viscosity, texture, and stability of the starch sols.

Chemical Properties

Molecular weight data on starch phosphates were neither found in the available literature nor submitted as unpublished data. It is likely that these ingredients are similar to other modified polysaccharide gums,⁴ varying primarily by phosphate

substitution and or/crosslinking. For example, carrageenan (a polysaccharide gum), has an average molecular weight > 100,000 Da and a molecular weight distribution of 196,000 - 257,000 Da. Properties data on some of the starch phosphates are presented in Table 2.

According to the *Food Chemicals Codex*, modified food starches usually occur as a white or nearly white powder or as intact granules that are insoluble in alcohol, in ether, and in chloroform, and when not pregelatinized, they are practically insoluble in cold water.⁹ During heating in water (i.e., pregelatinization), the granules usually begin to swell at temperatures between 45°C and 80°C, depending on the botanical origin and the degree of modification. They gelatinize completely at higher temperatures. Pregelatinized starches hydrate in cold water, and occur as flakes, amorphous powders, or coarse particles.

Method of Manufacture

The following methods of manufacturing are general to the production of starch phosphates, and it is unknown whether they are used in the manufacture of these ingredients for use in cosmetics

Distarch Phosphate

Distarch Phosphate (a modified starch) is obtained by esterification of food starch with sodium trimetaphosphate or phosphorus oxychloride.⁶ This treatment results in cross-linking, whereby a polyfunctional substituting agent, such as phosphorus oxychloride, connects two chains. Distarch Phosphate may also be subjected to acid, alkali, enzyme, or bleaching treatment. Additionally, Distarch Phosphate may be prepared by the combined use of sodium tripolyphosphate and sodium trimetaphosphate, which results in cross-linking and esterification of starch chains.⁶ The overall extent of modification is small, with the residual phosphate being in the order of 0.4% phosphorus.

Distarch Phosphate Acetate

Distarch Phosphate Acetate (a modified starch) is obtained by esterification/cross-linking of food starch with sodium trimetaphosphate or phosphorus oxychloride, combined with esterification with acetic anhydride or vinyl acetate.⁶ Acetylation results in substitution of hydroxyl groups with acetyl esters. Additionally, Distarch Phosphate Acetate may be subjected to acid, alkali, enzyme, or bleaching treatment.

Hydroxypropyl Starch Phosphate

Hydroxypropyl Starch Phosphate (a modified starch) is obtained by esterification of food starch with sodium trimetaphosphate or phosphorus oxychloride, combined with etherification by propylene oxide.⁷ Hydroxypropylation results in the substitution of hydroxyl groups with 2-hydroxypropyl ether. Additionally, Hydroxypropyl Starch Phosphate may be subjected to acid, alkali, enzyme, or bleaching treatment.

Modified Food Starches

According to the *Food Chemicals Codex*, starch is chemically modified by mild degradation reactions or by reactions between the hydroxyl groups of the native starch and the reactant selected.⁹ Either one or more of the following processes are used: mild oxidation (bleaching), moderate oxidation, acid and/or enzyme depolymerization, monofunctional esterification, polyfunctional esterification (cross-linking), monofunctional etherification, alkaline gelatinization, and certain combinations of these treatments.

Impurities

The JECFA purity specifications for Distarch Phosphate, Distarch Phosphate Acetate, and Hydroxypropyl Starch Phosphate for use as food additives are provided in Table 3.

Modified Food Starches

According to the *Food Chemicals Codex*, limitations on impurities in modified food starch include: lead (not more than 1 mg/kg), sulfur dioxide (not more than 0.005%), crude fat (not more than 0.15%), cereal starch (not more than 15%), potato starch (not more than 21%), sago starch (not more than 18%), tapioca starch (not more than 18%), and protein (not more than 0.5%; except in modified high-amylose starches, not more than 1%).⁹

USE

Cosmetic

The safety of the cosmetic ingredients addressed in this assessment is evaluated based on data received from the US Food and Drug Administration (FDA) and the cosmetics industry on the expected use of these ingredients in cosmetics. Use frequencies of individual ingredients in cosmetics are collected from manufacturers and reported by cosmetic product category in FDA's Voluntary Cosmetic Registration Program (VCRP) database. The cosmetic product categories named in the VCRP database indicate the intended uses of cosmetic ingredients, and are identified in 21 CFR Part 720. Data are submitted by the cosmetic industry in response to a survey conducted by the Personal Care Products Council (Council) of maximum reported use concentrations, also by product category. Neither the categories provided by the VCRP, nor those provided by the Council survey, include a designation for use via airbrush application. Airbrush devices, alone, are within the purview of the US

Consumer Product Safety Commission (CPSC), while ingredients used in airbrush devices are within the jurisdiction of the FDA. As airbrush technology use for cosmetics has neither been evaluated by the CPSC, nor the use of cosmetic ingredients in airbrush technology by the FDA, no US regulatory authority has evaluated the safety of this delivery methodology for cosmetic ingredients. Moreover, no consumer habits and practices data are available to evaluate the risks associated with this use type.

According to 2022 FDA VCRP data, Hydroxypropyl Starch Phosphate is reported to have the greatest frequency of use; it is reported to be used in 261 cosmetic products, 193 of which are rinse-offs.¹² The results of a concentration of use survey, conducted by the Council in 2020 and provided to CIR in 2021, indicate that Distarch Phosphate has the highest concentration of use; it is reported to be used at maximum use concentrations up to 7.5% in leave-on products. Further use data are presented in Table 4. According to VCRP and Council survey data, 1 of the starch phosphates (Distarch Phosphate Acetate) reviewed in this safety assessment is not currently in use in cosmetic products (Table 5).

Cosmetic products containing starch phosphates may incidentally come in contact with the eyes (e.g., Distarch Phosphate in eyeliners at concentrations up to 7.5%). Additionally, Distarch Phosphate is used in formulations that may be incidentally ingested (at up to 0.5% in lipstick) and some of these ingredients (e.g., Hydroxypropyl Starch Phosphate in bath soaps and detergents at up to 0.88%) are used in products that come in contact with mucous membranes.¹³

Distarch Phosphate is used in cosmetic products that could possibly be inhaled; it is reported to be used in hair sprays (aerosols) at concentrations up to 5.3%, and in face powders (concentrations not reported). In practice, as stated in the Panel's respiratory exposure resource document (<https://www.cir-safety.org/cir-findings>), most droplets/particles incidentally inhaled from cosmetic sprays would be deposited in the nasopharyngeal and tracheobronchial regions and would not be respirable (i.e., they would not enter the lungs) to any appreciable amount. Conservative estimates of inhalation exposures to respirable particles during the use of loose powder cosmetic products are 400-fold to 1000-fold less than protective regulatory and guidance limits for inert airborne respirable particles in the workplace.

Additionally, although products containing some of these ingredients may be marketed for use with airbrush technology, this information is not available from the VCRP or the Council survey. Without information regarding the frequency and concentrations of use of these ingredients (and without consumer habits and practices data related to this use technology), the data are insufficient to evaluate the safety thereof in airbrush applications.

The starch phosphates reviewed in this safety assessment are not restricted from use in any way under the rules governing cosmetic products in the European Union.¹⁴

Non-Cosmetic

According to the US FDA, under 21 CFR 172.892, food starch-modified is a food additive permitted for direct addition to food for human consumption, and may be safely used in food when it adheres to the modifications described in the CFR citation. The quantity of any substance employed to effect such modification shall not exceed the amount reasonably required to accomplish the intended physical or technical effect, nor exceed any limitation prescribed. To insure safe use of the food starch-modified, the label of the food additive container shall bear the name of the additive "food starch-modified" in addition to other information required by the Act. Food starch may be modified by the treatments prescribed in the CFR citation.

TOXICOKINETIC STUDIES

Toxicokinetic studies on the starch phosphates reviewed in this safety assessment were neither found in the published literature, nor were these data submitted. A general overview of how starch is metabolized in the body is provided. The metabolism of starch begins via a maltodextrin glucosidase resulting in a water molecule and a sucrose. D-Fructose is phosphorylated through an adenosine triphosphate (ATP) driven fructokinase resulting in the release of an adenosine diphosphate (ADP), a hydrogen cation and a β -D-fructofuranose-6-phosphate.¹⁵

TOXICOLOGICAL STUDIES

Acute Toxicity Studies

Oral

Distarch Phosphate

The acute oral toxicity of Distarch Phosphate was evaluated using various animal species in different experiments.⁵ However, details relating to the protocol and number and strain of animals tested were not stated. Test results were as follows: female mice (LD₅₀ > 24 g/kg), female mice (LD₅₀ > 19 g/kg), female rats (LD₅₀ > 20 g/kg), female rats (LD₅₀ > 35 g/kg), guinea pigs (LD₅₀ > 8.8 g/kg), guinea pigs (LD₅₀ > 18 g/kg), rabbits (LD₅₀ > 7 g/kg), rabbits (LD₅₀ > 10 g/kg), cats (LD₅₀ > 6 g/kg), and cats (LD₅₀ > 9 g/kg).

Short-Term, Subchronic, and Chronic Toxicity Studies

Repeated dose oral toxicity studies are presented in Table 6 and summarized below.

Distarch Phosphate

In a short-term study, groups of 10 rats were fed a basal diet with 0.9 or 3.6 g of Distarch Phosphate for 7 d; no significant differences in body weight gain or organ weights were noted between animals fed modified or unmodified starch in the diet.⁵ In another study, groups of 10 male rats were fed a basal diet supplemented with 1, 2, or 4 g unmodified starch or Distarch Phosphate for 10 d. Weight gains were identical at all 3 levels of supplementation, and no unusual behavioral reactions were observed. Necropsy results were normal in groups of male and female weanling Wistar-Purdue rats (number not stated) fed a diet supplemented with 1 or 2 g Distarch Phosphate over a 21-d period.^{5,16} Groups of 10 male and 10 female rats were fed a diet initially containing 10% Distarch Phosphate, and increasing to a concentration of 35%, for a total of 60 d; no test substance-related deaths or gross or histopathological changes were observed.⁵ In a subchronic study in which groups of 25 male and 25 female rats were fed diets containing 0.2, 1%, or 5% Distarch Phosphate (trimetaphosphate- modified starch) or unmodified starch for 90 d, there were no obvious gross or histopathological changes that were attributable to test substance administration. Two types of Distarch Phosphate (0.085% esterified and 0.128% esterified phosphate) were administered in the diet at concentrations of 5%, 15%, and 45% to groups of 10 male and 10 female rats for 90 d; test substance-related abnormalities were not observed at gross or histopathologic examination. In a chronic toxicity study, groups of 30 male and 30 female Wistar rats were fed Distarch Phosphate (maize starch 'white milo,' cross-linked with sodium trimetaphosphate up to 0.04% introduced phosphorus and esterified with sodium tripolyphosphate up to a total content of 0.35% bound phosphorus) at dietary levels of 0%, 5%, 10%, or 30% (equivalent to 0, 2500, 5000, or 15,000 mg/kg bw/d, respectively) for 104 wk.^{5,17} Relative organ weights were comparable to those of the controls, except for significantly decreased spleen weight in males and significantly increased spleen and kidney weights in females fed at 30%. When compared to controls, the males fed the 30% concentration had a slightly increased degree and incidence of focal hyperplasia of the renal papillary and pelvic epithelium. (Results relating to carcinogenicity are included in that section of this report.)

Groups of 8 miniature pigs (Pitman-Moore strain) were fed formula diets containing 5.4% unmodified starch or 5.6% Distarch Phosphate for 25 d.⁵ At the end of the study, serum chemistry values and relative organ weights in test and control animals were similar. Groups of 3 male and 3 female Beagle dogs were given gelatin capsules containing 50, 250, or 1250 mg/kg bw/d Distarch Phosphate for 90 d; no adverse gross or microscopic effects were reported.⁸

Distarch Phosphate Acetate

A short-term study was conducted in groups of 10 male and 10 female rats given 25% or 50% Distarch Phosphate Acetate (cross-linked with 0.02% phosphorus oxychloride and acetylated with 8% acetic anhydride; acetyl content of 2.33%) in the diet (equivalent to 30,000 and 60,000 mg/kg bw/d, respectively) for 7 d; moderate diarrhea was observed in both sexes of the 50% group.⁸ In an 8-wk study with the same test article, groups of 10 male and 10 female rats were fed 0%, 25%, or 50% of Distarch Phosphate Acetate in their diet (equivalent to 0, 22,500, and 45,000 mg/kg bw/d, respectively); histological examination indicated no abnormalities when compared to the control. In a chronic toxicity study, groups of 25 female Sprague-Dawley rats were fed Distarch Phosphate Acetate (equivalent to 15,000 mg/kg bw/d) or 30% unmodified starch (used as a control); this comprised a 1-yr study in weanling rats (experiment 1) and a separate 9-month study utilizing 9-mo-old rats (experiment 2).^{8,18} No treatment-related histopathological effects were observed in the uterus or lower urinary tract, liver, parathyroid, cecum, or ovaries in either experiment. Histopathological examination of kidney sections demonstrated the presence of treatment-related pelvic nephrocalcinosis. In a 2-yr study, groups of 30 male and 30 female Wistar-derived rats were fed Distarch Phosphate Acetate (potato starch cross-linked with 0.02% phosphorus oxychloride and acetylated with 8% acetic anhydride; acetyl content of 2.33%) at dietary levels of 0%, 5%, 10%, or 30% (equivalent to 0, 2500, 5000, or 15,000 mg/kg bw/d, respectively); the only treatment-related effect that was observed histologically was a kidney lesion, which occurred at a higher incidence in high-dose males.^{8,17} (Results relating to carcinogenicity are included in that section of this report.)

Histopathological evaluation of the liver and kidney showed no treatment-related effects in groups of 10 male and 10 female Syrian golden hamsters fed a diet containing 30% Distarch Phosphate Acetate for 30 d. No significant abnormalities were found in pigs (8/group) fed 0%, 5%, 15%, or 25% Distarch Phosphate Acetate (equivalent to 0, 1250, 2500 and 6250 mg/kg bw/d, respectively) in the diet for 14 wk; histological examination was not performed on animals that survived until study termination. Additionally, gross and histopathological examination revealed no abnormalities in pigs (4 males and 4 females/group) fed 0%, 35%, or 70% Distarch Phosphate Acetate (equivalent to 0, 8750, or 17,500 mg/kg bw/d, respectively) in the diet over a 14.5-wk period.⁸

Hydroxypropyl Starch Phosphate

Groups of 10 male rats were fed diets containing 25%, 50%, 75%, or 100% Hydroxypropyl Starch Phosphate (equivalent to 30,000, 60,000, 90,000, or 120,000 mg/kg bw/d, respectively) in a short-term (28-d) study.⁸ No histological abnormalities were observed in the heart, liver, spleen, kidney and cecum. Groups of 15 male and 15 female weanling FDRL Wistar rats were fed diets containing 5%, 10%, or 25% Hydroxypropyl Starch Phosphate (starch modified with 10% propylene oxide; equivalent to 4500, 9000, or 22,500 mg/kg bw/d, respectively) in a subchronic (90-d) study. Histopathological examination indicated that more than half that rats in each test groups had mineralization of the renal pelvis. Except for a slight thinning of the ceca (without histopathological changes), no other test substance-related changes were observed. In another 90-d study,

groups of 15 male and 15 female rats were fed diets containing 0%, 5%, 10%, or 25% of a Hydroxypropyl Starch Phosphate (prepared by treating cornstarch with 0.1% phosphorus oxychloride and 5% propylene oxide; equivalent to 4500, 9000, and 22,500 mg/kg bw/d). Males of the highest dose group had slightly decreased relative weights of the testes; no macroscopic test substance-related differences were observed among the various groups. In a chronic toxicity study, groups of 75 male and 75 female Swiss albino SPF mice were fed a diet containing 55% Hydroxypropyl Starch Phosphate (equivalent to 27,500 mg/kg bw/d) or a control diet containing 55% pregelatinized potato starch for 89 wk.^{8,19} Histopathological evaluation revealed an increase in the incidence of intratubular mineralization in the kidneys of treated male and female mice. (Results relating to carcinogenicity are included in that section of this report.)

DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES

Oral

Distarch Phosphate

A three-generation study on Distarch Phosphate (maize starch 'white milo,' cross-linked with sodium trimetaphosphate up to 0.04% introduced phosphorus and esterified with sodium tripolyphosphate up to a total content of 0.35% bound phosphorus) was performed using groups of 10 male and 20 female rats (Wistar-derived) of the parental (P), F₁ and F₂ generations, to produce 2 successive litters in each generation by mating at weeks 12 and 20 after weaning.¹⁷ A total of 10 males and 10 females of the F_{1b} generation were maintained for 3 wk after weaning, and then killed for histopathological studies. The P, F_{1b}, and F_{2b} parents were used for determination of implantation sites. The F_{3b} generation was maintained for 3 wk after weaning and then killed for histopathological evaluation. The test substance was fed at 10% in the diet (equal to 5000 mg/kg bw/d). The control group was fed unmodified potato starch. No adverse effects were noted regarding appearance, behavior, body weight, fertility, litter size, resorption quotient, weights of pups, and mortality. Cecal weights were not increased, except for the filled cecum weight of F₁ male parents. The spleen weight of F_{3b} females was increased significantly ($p < 0.01$). Gross and macroscopic examination did not reveal histopathological changes that were attributable to ingestion of the starch.

Distarch Phosphate Acetate

A three-generation study on Distarch Phosphate Acetate (potato starch cross-linked with 0.02% phosphorus oxychloride and acetylated with 8% acetic anhydride; acetyl content of 2.33%) was performed using groups of 10 male and 20 female rats (Wistar-derived) of the P, F₁ and F₂ generations, to produce 2 successive litters in each generation by mating at weeks 12 and 20 after weaning.¹⁷ The study was performed according to the procedure in the study immediately above. The test substance was fed at 10% of the diet (equivalent to 5000 mg/kg bw/d). No adverse effects were noted with respect to health, behavior, mortality, growth, fertility, litter size, resorption quotient, weaning weight or mortality of the young. Cecal weight of parental rats fed the modified starch was not increased. Macroscopic examination did not reveal treatment-related effects in F_{3b} rats. Relative thyroid weight in males was decreased ($p < 0.05$), and a slightly increased cecum weight in females ($p < 0.05$) was observed. Histopathologic examination did not reveal any treatment-related changes.

GENOTOXICITY STUDIES

In Silico

Distarch Phosphate, Distarch Phosphate Acetate, and Hydroxypropyl Starch Phosphate

According to EFSA, in the absence of genotoxicity data on modified starches, an evaluation of genotoxicity was performed in silico.⁸ On this basis, the identification of structural alerts for genotoxicity for the following starch phosphates was performed using the Organisation for Economic Co-operation and Development (OECD) quantitative structure-activity relationship (QSAR) Toolbox (version 3.3.5.17): Distarch Phosphate, Distarch Phosphate Acetate, and Hydroxypropyl Distarch Phosphate. No relevant structural alerts for genotoxicity were highlighted for any of the 3 ingredients.

CARCINOGENICITY STUDIES

Oral carcinogenicity data are presented in Table 7 and summarized below.

Distarch Phosphate, Distarch Phosphate Acetate, and Hydroxypropyl Starch Phosphate were not carcinogenic in oral feeding studies. In one study, groups of 30 male and 30 female Wistar rats were fed Distarch Phosphate (maize starch 'white milo,' cross-linked with sodium trimetaphosphate up to 0.04% introduced phosphorus and esterified with sodium tripolyphosphate up to a total content of 0.35% bound phosphorus) at dietary levels of 0%, 5%, 10%, or 30% (equivalent to 0, 2500, 5000, and 15,000 mg/kg bw/d, respectively) for 104 wk.^{8,17} A similar 104-wk dietary feeding experiment on Distarch Phosphate Acetate (potato starch cross-linked with 0.02% phosphorus oxychloride and acetylated with 8% acetic anhydride; acetyl content of 2.33%) was performed using groups of rats (same strain and numbers of animals).^{8,17} No treatment-related effect was observed on the pattern of neoplasm development. In a third study, groups of 75 male and 75 female Swiss albino SPF mice were fed a diet containing 55% Hydroxypropyl Starch Phosphate (equivalent to 27,500 mg/kg bw/d) or a control diet

containing 55% pregelatinized potato starch for 89 wk.^{8,19} Other results relating to chronic oral toxicity from these studies are included in that section of this report.

DERMAL IRRITATION AND SENSITIZATION STUDIES

The skin irritation and sensitization studies summarized below are presented in Table 8.

An eyeliner containing 7.181% Distarch Phosphate was not a sensitizer in a maximization test with sodium lauryl sulfate (SLS) pretreatment (applied neat; 25 subjects).²⁰ A conditioner containing 2% Hydroxypropyl Starch Phosphate, tested as a 25% aqueous solution of the formulation (Hydroxypropyl Starch Phosphate effective concentration = 0.5%), was not an irritant in a 24-h single occlusive insult patch test (SIOPT; 15 subjects)²¹ or a sensitizer in a human repeated insult patch test (HRIPT; 104 subjects).²²

OCULAR IRRITATION STUDIES

Data on the ocular irritation potential of the starch phosphates reviewed in this safety assessment were neither found in the published literature, nor were these data submitted.

CLINICAL STUDIES

Other Clinical Reports

Distarch Phosphate

On each of 4 successive days, 12 volunteers consumed 60 g of Distarch Phosphate (maize starch 'white milo,' cross-linked with sodium trimetaphosphate up to 0.04% introduced phosphorus and esterified with sodium tripolyphosphate up to a total content of 0.35% bound phosphorus).⁸ No abnormalities were observed. (No other details were provided.)

Distarch Phosphate Acetate

Twelve volunteers consumed (on each of 4 successive days) 60 g of Distarch Phosphate Acetate (potato starch cross-linked with 0.02% phosphorus oxychloride and acetylated with 8% acetic anhydride; acetyl content of 2.33%).⁸ No abnormalities were observed with regard to frequency and amount of feces, as well as fecal water and lactic acid content. No other adverse effects were noted. (No other details were provided.)

SUMMARY

The safety of 4 starch phosphates (all modified starches) as used in cosmetics is reviewed in this safety assessment. Modified food starches are defined in the *Food Chemicals Codex* as products of the treatment of any of several grain- or root-based native starches (for example, corn, sorghum, wheat, potato, tapioca, and sago) with small amounts of certain chemical agents that modify the physical characteristics of the native starches to produce desirable properties. According to the *Dictionary*, Distarch Phosphate functions as an anticaking agent and binder. Viscosity increasing agent is a common cosmetic function of Distarch Phosphate Acetate, Hydroxypropyl Starch Phosphate, and Sodium Hydroxypropyl Starch Phosphate.

Distarch Phosphate, Distarch Phosphate Acetate, and Hydroxypropyl Starch Phosphate are obtained by esterification of food starch.

According to 2022 FDA VCRP data, Hydroxypropyl Starch Phosphate is reported to be used in 261 cosmetic products. Of the 4 starch phosphates reviewed in this safety assessment, this is the greatest reported use frequency. The results of a concentration of use survey, conducted by the Council in 2020 and provided in 2021, indicate that Distarch Phosphate has the highest concentration of use; it is reported to be used at maximum use concentrations up to 7.5% in leave-on products. According to VCRP and Council survey data, Distarch Phosphate Acetate is not currently in use in cosmetic formulations.

The acute oral toxicity of Distarch Phosphate was evaluated using various animal species in different experiments. However, details relating to the protocol and number and strain of animals tested were not stated. The following acute oral LD₅₀ values have been reported for Distarch Phosphate: female mice (LD₅₀ > 24 g/kg), female mice (LD₅₀ > 19 g/kg), female rats (LD₅₀ > 20 g/kg), female rats (LD₅₀ > 35 g/kg), guinea pigs (LD₅₀ > 8.8 g/kg), guinea pigs (LD₅₀ > 18 g/kg), rabbits (LD₅₀ > 7 g/kg), rabbits (LD₅₀ > 10 g/kg), cats (LD₅₀ > 6 g/kg), and cats (LD₅₀ > 9 g/kg).

In a short-term feeding studies involving groups of 10 rats (strains not stated) fed Distarch Phosphate (doses up to 4 g in diet) for 7 or 10 d, there were no significant differences in body or organ weights when compared to rats fed a basal diet. Necropsy results were normal in groups of weanling rats (Wistar-Purdue strain, number not stated) fed Distarch Phosphate (up to 2 g) in the diet for 21 d. Similarly, no gross/histopathological changes were observed in groups of 20 rats (strains not stated) fed 10% to 35% Distarch Phosphate in the diet for 60 d. Groups of 8 miniature pigs (Pitman-Moore strain) were fed formula diets containing 5.6% Distarch Phosphate for 25 d. Serum chemistry values and relative organ weights in test and control animals were similar. Groups of 20 rats (CIVO colony, Wistar-derived) were given 25% and 50% Distarch Phosphate Acetate in the diet (equal to 30,000 and 60,000 mg/kg bw/d, respectively) for 7 d. Moderate diarrhea occurred at the higher

concentration, and there was no evidence of hair loss. When the same test substance was fed (22,500 and 45,000 mg/kg bw/d) to groups of 20 rats of the same strain for 30 d, no abnormalities were observed at histopathological evaluation. Histopathological evaluation of the liver and kidney showed no treatment-related effects in groups of 10 male and 10 female Syrian golden hamsters fed a diet containing 30% Distarch Phosphate Acetate for 30 d. Histological abnormalities also were not observed in a study in which groups of 10 male rats (strain not stated) were fed up to 100% Hydroxypropyl Starch Phosphate (120,000 mg/kg bw/d) in the diet for 28 d.

In a subchronic feeding study, groups of 25 male and 25 female rats (strain not stated) were fed diets containing Distarch Phosphate at concentrations up to 5% for 90 d. There were no test substance-related gross or histopathological changes. Similarly, neither gross nor histopathologic changes were observed when Distarch Phosphate was administered to groups of 20 rats (strain not stated) at dietary concentrations up to 45% for 90 d. In another study, groups of 6 Beagle dogs were given Distarch Phosphate (in gelatin capsules, doses up to 1250 mg/kg bw/day) for 90 d. No adverse effects were noted at gross or histopathologic examination. When groups of 8 pigs (strain not stated) were fed Distarch Phosphate Acetate at dietary concentrations up to 25% (up to 6250 mg/kg bw/d) for 14 wk, no significant abnormalities were observed at post-mortem examination. Similarly, results from gross and histopathological examinations were negative in groups of 8 pigs (strain not stated) fed Distarch Phosphate Acetate at concentrations up to 70% (up to 17,500 mg/kg bw/d) for 14.5 wk. Groups of 30 weanling rats (FDRL Wistar) were fed diets containing 5%, 10%, or 25% of Hydroxypropyl Starch Phosphate (equivalent to 4500, 9000, and 22,500 mg/kg bw/d) for a period of 90 d. Histopathological examination revealed mineralization of the renal pelvis in each of the 3 dietary groups. In another study (same duration and dietary concentrations), no macroscopic test substance-related changes were observed among the 3 dietary groups (groups of 30 rats; strain not stated).

Groups of 25 female Sprague-Dawley rats were fed 30% Distarch Phosphate Acetate (equivalent to 15,000 mg/kg bw/d) in the diet in a 1-yr study involving weanling rats and in a separate 9-mo study involving 9-mo-old rats. Histopathological examination of kidney sections revealed treatment-related pelvic nephrocalcinosis; no other histopathological effects were observed. In another chronic study, groups of 60 rats (Wistar-derived) were fed Distarch Phosphate at dietary levels up to 30% (equivalent to 15,000 mg/kg bw/d) for 104 wk. When compared to controls, male rats in this highest dietary concentration group had a slightly increased degree and incidence of focal hyperplasia of the renal papillary and pelvic epithelium. Significantly decreased spleen weight in males and significantly increased spleen and kidney weights in females were also noted in this dietary group. Groups of 60 rats (Wistar-derived) were fed Distarch Phosphate Acetate at dietary levels of 0%, 5%, 10% and 30% (equal to 0, 2500, 5000 and 15,000 mg/kg bw/d, respectively) for 104 wk. The only treatment-related effect observed histologically was a kidney lesion, which occurred at a higher incidence in high-dose males. Groups of 75 male and 75 female Swiss albino SPF mice were fed a diet containing 55% Hydroxypropyl Starch Phosphate (equivalent to 27,500 mg/kg bw/d) for 89 wk. An increased incidence of intratubular mineralization in the kidneys was observed at histopathological examination.

A three-generation study was performed using groups of 10 male and 20 female rats (Wistar-derived) of the P, F₁ and F₂ generations to produce two successive litters in each generation by mating at wk 12 and 20 after weaning. Distarch Phosphate was fed at a concentration of 10% in the diet (equivalent to 5000 mg/kg bw/d). No adverse effects on fertility, litter size, resorption quotient, or weights of pups were observed. A study on Distarch Phosphate Acetate (same dietary concentration and protocol) yielded the same results.

A genotoxicity evaluation of modified starches was performed *in silico*. The identification of structural alerts for genotoxicity of the following starch phosphates was evaluated using the OECD QSAR Toolbox: Distarch Phosphate, Distarch Phosphate Acetate, and Hydroxypropyl Distarch Phosphate. No relevant structural alerts for genotoxicity were highlighted for any of the 3 ingredients.

Groups of 30 male and 30 female rats (Wistar-derived) were fed Distarch Phosphate at dietary levels of 5%, 10%, and 30% (equivalent to 2500, 5000 and 15,000 mg/kg bw/d, respectively) for 104 wk. There was no indication of carcinogenicity. In a similar study on Distarch Phosphate Acetate (same dietary concentration and protocol), no treatment-related effect was observed on the pattern of neoplasm development. There was no evidence of carcinogenicity in a study in which groups of 75 male and 75 female Swiss albino SPF mice were fed a diet containing 55% Hydroxypropyl Starch Phosphate (equivalent to 27,500 mg/kg bw/d) for 89 wk.

An eyeliner containing 7.181% Distarch Phosphate was not a sensitizer in a maximization test using SLS pretreatment (applied neat; 25 subjects). A conditioner containing 2% Hydroxypropyl Starch Phosphate, tested as a 25% aqueous solution of the formulation (Hydroxypropyl Starch Phosphate effective concentration = 0.5%), was neither an irritant in a 24-h SIOPT (15 subjects), nor a sensitizer in an HRIPT (104 subjects).

No abnormalities were observed after 12 volunteers consumed, on each of 4 successive days, 60 g Distarch Phosphate. Similarly, no adverse effects were observed when 12 volunteers consumed 60 g Distarch Phosphate Acetate according to the same procedure.

DISCUSSION

This assessment reviews the safety of 4 starch phosphates as used in cosmetic formulations. The Panel reviewed the available data and concluded that these ingredients are safe in cosmetics in the present practices of use and concentration described in the safety assessment.

The Panel noted the complete and favorable data profile for the ingredients in this report, and determined that these data were sufficient to support the safety of all 4 starch phosphates. Safety was further supported by the fact that food starch-modified may be used as a food additive permitted for direct addition to food for human consumption. (All 4 ingredients are modified starches.) Additionally, the Panel noted the available irritation and sensitization data, particularly the negative human maximization test of an eyeliner containing 7.181% Distarch Phosphate.

The Panel discussed the issue of incidental inhalation exposure that could result with the use of formulations that contain these ingredients (e.g., Distarch Phosphate is reported to be used in hair sprays at concentrations up to 5.3% and in face powders (concentrations not reported)). Inhalation toxicity data were not available. However, the Panel noted that the majority of droplets/particles would not be respirable to any appreciable amount. Furthermore, droplets/particles deposited in the nasopharyngeal or tracheobronchial regions of the respiratory tract present no toxicological concerns based on the chemical and biological properties of these ingredients. Coupled with the small actual exposure in the breathing zone and the low concentrations at which these ingredients are used (or expected to be used) in potentially inhaled products, the available information indicates that incidental inhalation would not be a significant route of exposure that might lead to local respiratory or systemic effects. A detailed discussion and summary of the Panel's approach to evaluating incidental inhalation exposures to ingredients in cosmetic products is available in the respiratory exposure resource document at <https://www.cir-safety.org/cir-findings>.

CONCLUSION

The Expert Panel for Cosmetic Ingredient Safety concluded that the following 4 starch phosphates are safe in cosmetics in the present practices of use and concentrations described in this safety assessment:

Distarch Phosphate
Distarch Phosphate Acetate*

Hydroxypropyl Starch Phosphate
Sodium Hydroxypropyl Starch Phosphate

**Not reported to be in current use. Were this ingredient in this group not in current use to be used in the future, the expectation is that it would be used in product categories and at concentrations comparable to others in this group.*

TABLES

Table 1. Definitions and functions of the ingredients in this safety assessment.¹

Ingredient/CAS No.	Definition	Function(s)
Distarch Phosphate 55963-33-2	Distarch Phosphate is the product formed by the cross-linking of starch with sodium metaphosphate.	anticaking agents; binders
Distarch Phosphate Acetate 68130-14-3	Distarch Phosphate Acetate is the product obtained by the reaction of Distarch Phosphate with acetic anhydride.	emulsion stabilizers; viscosity increasing agents - aqueous
Hydroxypropyl Starch Phosphate 113894-92-1 39346-84-4 53124-00-8	Hydroxypropyl Starch Phosphate is the hydroxypropyl ether of Distarch Phosphate	bulking agents; viscosity increasing agents - aqueous
Sodium Hydroxypropyl Starch Phosphate 221355-22-2	Sodium Hydroxypropyl Starch Phosphate is the sodium salt of a 2-hydroxypropyl ether of Distarch Phosphate	abrasives; bulking agents; viscosity increasing agents - aqueous

Table 2. Chemical properties

Property	Value/Results	Reference
Distarch Phosphate		
Form	White or nearly white powder or granules or (if pregelatinized) flakes, or amorphous powder or coarse particles.	6
Solubility	Insoluble in cold water (if not pre-gelatinized); forming typical colloidal solutions with viscous properties in hot water; insoluble in ethanol	6
Distarch Phosphate Acetate		
Form	White or nearly white powder or granules or (if pregelatinized) flakes, or amorphous powder or coarse particles	6
Solubility	Insoluble in cold water (if not pre-gelatinized); forming typical colloidal solutions with viscous properties in hot water; insoluble in ethanol	6
Hydroxypropyl Starch Phosphate		
Form	White or nearly white powder or granules or (if pregelatinized) flakes, or amorphous powder or coarse particles	7
Solubility	Insoluble in cold water (if not pre-gelatinized); forming typical colloidal solutions with viscous properties in hot water; insoluble in ethanol	7

Table 3. JECFA specifications for purity⁶

	Distarch Phosphate	Distarch Phosphate Acetate	Hydroxypropyl Starch Phosphate
loss on drying (120°C, 4 h, vacuum not exceeding 100 mm Hg)	cereal starch: not more than 15.0% potato starch: not more than 21.0% other starches: not more than 18.0%	cereal starch: not more than 15.0% potato starch: not more than 21.0% other starches: not more than 18.0%	cereal starch: not more than 15.0% potato starch: not more than 21.0% other starches: not more than 18.0%
residual phosphate	*potato or wheat starch: not more than 0.5% *other starches: not more than 0.4%	NA	*potato or wheat starch: not more than 0.14% *other starches: 0.04%
acetyl groups	NA	*not more than 2.5%	NA
hydroxypropyl groups	NA	NA	*not more than 7.0%
propylene chlorohydrin	NA	NA	Not more than 1 mg/kg
phosphate (calculated as phosphorus)	NA	*potato and wheat starch: not more than 0.14% *other starches: 0.04%	NA
vinyl acetate	NA	Not more than 0.1 mg/kg	NA
sulfur dioxide	*cereal starches: not more than 50 mg/kg *other modified starches: not more than 10 mg/kg	*modified cereal starches: not more than 50 mg/kg *other modified starches: not more than 10 mg/kg	*modified cereal starches: not more than 50 mg/kg *other modified starches: not more than 10 mg/kg
lead	*not more than 2 mg/kg	*not more than 2 mg/kg	*not more than 2 mg/kg
manganese	*not more than 50 mg/kg	*not more than 50 mg/kg	*not more than 50 mg/kg
carboxyl groups	*not more than 0.1%	*not more than 0.1%	*not more than 0.1%

NA – not applicable

*on a dried basis

Table 4. Frequency (2022) and concentration (2021) of use according to duration and type of exposure.^{12,13}

	# of Uses	Max Conc of Use (%)	# of Uses	Max Conc of Use (%)	# of Uses	Max Conc of Use (%)
	Distarch Phosphate		Hydroxypropyl Starch Phosphate		Sodium Hydroxypropyl Starch Phosphate	
Totals*/Conc. Range	81	0.5 – 7.5	261	0.0034 – 6.2	17	2.5 – 4.5
Duration of Use						
<i>Leave-On</i>	76	0.5 – 7.5	68	0.3 - 3.3	2	2.5
<i>Rinse off</i>	5	NR	193	0.0034 - 6.2	15	4.5
<i>Diluted for (bath) Use</i>	NR	NR	NR	NR	NR	NR
Exposure Type						
Eye Area	4	3.7 – 7.5	1	1.9	NR	NR
Incidental Ingestion	5	0.5	NR	NR	NR	NR
Incidental Inhalation- Sprays	20 ^a ;31 ^b	5.3	34 ^a ;18 ^b	0.3 -1.4 ^a	1 ^a ;1 ^b	NR
Incidental Inhalation- Powders	15;31 ^b	NR	18 ^b	3.3 ^c	1 ^b	2.5 ^c
Dermal Contact	76	3.7 – 7.5	185	0.0034 - 3.3	16	2.5 – 4.5
Deodorant (underarm)	NR	NR	NR	0.88	NR	NR
Hair - Non-Coloring	NR	5.3	47	0.3-6.2	1	NR
Hair-Coloring	NR	NR	29	2 – 2.7	NR	NR
Nail	NR	NR	NR	NR	NR	NR
Mucous Membrane	5	0.5	113	0.88	NR	NR
Baby Products	NR	NR	2	NR	NR	NR

NR = Not Reported

* Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

^a It is possible that these products may be sprays, but it is not specified whether the reported uses are sprays^b Not specified these products are sprays or powders, but it is possible the use can be as a spray or powder, therefore the information is captured in both categories^c It is possible that these products may be powders, but it is not specified whether the reported uses are powders**Table 5.** No reported uses.^{12,13}

Distarch Phosphate Acetate

Table 6. Repeated dose oral toxicity studies

Ingredient	Animals/Group	Study Duration	Vehicle	Dose/Concentration/Protocol	Results	Reference
Short-Term Toxicity Studies						
Distarch Phosphate (starch modified using trimetaphosphate)	10 rats (strain not stated)	7 d	basal diet (4 g)	0.9 g or 3.6 g (modified or unmodified starch). After feeding period, body weight gain and weights of following organs recorded: liver, kidney, heart, and spleen. Additional protocol details not included	No significant differences between modified and unmodified starches, when body and organ weights were compared.	⁵
Distarch Phosphate (same as above)	10 male rats (strain not stated)	10 d	basal diet (5 g)	1 g, 2 g, or 4 g (unmodified or modified starch). Additional protocol details not included	Weight gains identical when the 3 doses were compared. No unusual behavioral reactions observed	⁵
Distarch Phosphate (same as above)	male and female weanling rats (Wistar-Purdue strain; number/group not stated)	21 d	diet (5 g)	diet supplemented with 1 g or 2 g (modified or unmodified starch)	Weight gains comparable for modified and unmodified starches tested. Necropsy results normal	^{5,16}
Distarch Phosphate (same as above)	10 male and 10 female rats (strain not stated)	60 d	diet	10%, and increasing to concentration of 35%. Additional details relating to test protocol not included	Consistent, reduced rate of weight gain throughout study observed in female rats. All animals behaved normally. Four test and 2 control (treatment details not provided) rats died during study; findings considered unrelated to test substance administration. Hematological examination and urinalysis were normal and comparable in various groups. In male rats, liver weights were lower when compared to controls. Kidney weights were lower in both sexes. Authors noted that findings relating to liver and kidney weights were not associated with any gross or histopathological changes	⁵
Distarch Phosphate	8 miniature pigs (Pitman-Moore strain)	25 d	Formula diet	Formula diet containing 5.6% Distarch Phosphate or 5.4% unmodified starch	Growth described as normal during study. At end of study, hemoglobin and the following serum chemistry values in test and control animals were similar: cholesterol, triglyceride, calcium, phosphorus, alkaline phosphatase, urea nitrogen, total protein, albumin, and globulin. Also, values for relative organ weight, carcass composition (water, fat, calcium, phosphate, sodium, and magnesium) and liver composition (water, fat, protein, and ash) in test animals were similar to those in control animals.	⁵
Distarch Phosphate Acetate (cross-linked with 0.02% phosphorus oxychloride and acetylated with 8% acetic anhydride; acetyl content of 2.33%)	10 male and 10 female rats (CIVO colony, Wistar-derived)	7 d	diet	25% and 50% (equal to 30,000 and 60,000 mg/kg bw/d, respectively). Thereafter, 4% cellulose added in diet for additional 3 d	Body weights slightly reduced (at 50% concentration) in both sexes after 7 d. Fecal dry matter increased in all test groups. Moderate diarrhea (at 50% concentration) in both sexes, and was unaffected by feeding of additional cellulose in diet. No loss of hair noted	⁸
Distarch Phosphate Acetate (cross-linked with 0.02% phosphorus oxychloride and acetylated with 8% acetic anhydride; acetyl content of 2.33%)	10 male and 10 female rats (CIVO colony, Wistar derived)	8 wk	diet	25% and 50% (equal to 22,500 and 45,000 mg/kg bw/d, respectively). Control group received diet only	Differences in body weights not statistically significant. At 50% concentration, body weights of males slightly lower when compared to control and dosing with 25% concentration. Water content of feces higher in males, but not in females. Feces dry matter increased in both sexes at 50% concentration, and slight increase at 25% concentration. Incidence of diarrhea insignificant. Dose-related increase in cecal weight in both sexes. histological examination showed no abnormalities, when compared to control.	⁸

Table 6. Repeated dose oral toxicity studies

Ingredient	Animals/Group	Study Duration	Vehicle	Dose/Concentration/Protocol	Results	Reference
Distarch Phosphate Acetate	10 male and 10 female Syrian golden hamsters	30 d	diet	30% Distarch Phosphate Acetate or 30% untreated starch	Hamsters fed 30% Distarch Phosphate Acetate showed slightly lower daily intake (statistics not reported); daily body weight gain comparable or slightly higher when compared to control. No effects observed at hematological examination, clinical chemistry examination, or urinalysis. Histopathological evaluation of liver and kidney revealed no treatment-related effects. No additional details provided.	⁸
Hydroxypropyl Starch Phosphate	10 male rats (strain not stated)	28 d	diet	25%, 50%, 75% and 100% (equivalent to 30,000, 60,000, 90,000 and 120,000 mg/kg bw/d, respectively)	At highest doses tested, growth and body weights were reduced, compared to controls. At same doses, relative liver weights slightly increased, compared to controls fed food grade, unmodified starch. Relative organ weights of empty ceca increased at all doses tested. No histological abnormalities observed in heart, liver, spleen, kidney and cecum.	⁸
Subchronic Toxicity Studies						
Distarch Phosphate (starch modified using trimetaphosphate)	25 male and 25 female rats (strain not stated)	90 d	diet	diets containing t Distarch Phosphate or unmodified starch at concentrations of 0.2%, 1%, and 5%	Animal deaths included 11 controls (treatment details not provided) and 3 test animals, all with intercurrent disease. Organ weights and hematological examination (at days 45 and 90) classified as normal in test and control groups. Pooled urinalysis comparable for all groups. No obvious gross or histopathological changes attributable to feeding with any concentration	⁵
Distarch Phosphate (0.085% esterified and 0.128% esterified phosphate)	10 male and 10 female rats (strain not stated)	90 d	diet	5%, 15%, and 45%	When compared to controls, no treatment-related abnormal changes in the following: general appearance, behavior, mortality, food consumption, hematology, serum chemistry and urinalysis. Test substance-related abnormalities not observed at gross or histopathologic examination	⁵
Distarch Phosphate	3 male and 3 female Beagle dogs	90 d	gelatin capsule	50, 250 and 1250 mg/kg bw	No significant differences in body weight among the groups. Food consumption was comparable for all groups. No untoward behavioral reactions noted during entire testing period. Results of hematology, clinical blood chemistry, urine analyses, and liver function tests negative for significant abnormalities. Gross or histopathological findings showed no adverse effects. Organ weight data and organ-body weight ratios calculated did not reveal any significant inter-group differences	⁸
Distarch Phosphate Acetate	8 pigs (strain not stated)	14 wk	diet	0%, 5%, 15% and 25% (equivalent to 0, 1250, 2500 and 6250 mg/kg bw/d)	No effect on growth, food consumption, hematology or biochemistry. One pig (treatment group not specified) died of unknown causes. No significant abnormalities found post-mortem, but histological examination was not performed, except for the animal that died	⁸
Distarch Phosphate Acetate	4 male and 4 female pigs (strain not stated)	14.5 wk	diet	0%, 35% or 70% Distarch Phosphate Acetate (equivalent to 0, 8750 and 17,500 mg/kg bw/d, respectively)	Growth rate and food consumption satisfactory. Hematology, blood chemistry, and urinalysis revealed no treatment-related abnormalities. Ophthalmoscopy showed no test substance-related abnormalities. Organ weights and gross and histopathological examinations revealed no abnormalities in test or control groups. Three pigs in higher dose group died suddenly at various intervals during study, without any evidence relating to cause of death. In one of the 3 pigs, evidence of neurological disorders observed before death. Neurological disorders also observed in 1 animal of 35% concentration group, although animal recovered. No histopathological evidence of nervous system involvement noted in any animal.	⁸

Table 6. Repeated dose oral toxicity studies

Ingredient	Animals/Group	Study Duration	Vehicle	Dose/Concentration/Protocol	Results	Reference
Hydroxypropyl Starch Phosphate (modified with 10% propylene oxide)	15 male and 15 female weanling rats FDRL_Wistar strain)	90 d	diet	5%, 10% or 25% (equivalent to 4500, 9000 and 22,500 mg/kg bw/d, respectively), or 25% unmodified starch	Four rats died during test period, but deaths were not treatment-related. At the highest dose, feces were soft and bulky during first 7 wk, but normal for remainder of study. Growth, food intake, and food efficiency of all groups were normal, except for a slight decrease in feed efficiency in males of 25% modified starch group. Hematological, biochemical, and urine analyses within normal limits. At necropsy, absolute and relative organ weights of the test and control animals were comparable, except for cecum. Full cecum weights showed treatment-related response; however, in case of empty ceca, significant increase in weight observed only in males on 25% diet. Histopathological examination showed that several rats in test groups had mineralization of renal pelvis (5% group: 18/30; 10% group: 20/30; and 25% group: 22/30). No other test substance-related changes observed, with exception of slight thinning of ceca, which was not accompanied by histopathological changes	⁸
Hydroxypropyl Starch Phosphate (prepared by treating cornstarch with 0.1% phosphorus oxychloride and 5% propylene oxide)	15 male and 15 female rats (strain not stated)	90 d	diet	0%, 5%, 10% and 25% (equivalent to 4500, 9000 and 22,500 mg/kg bw/d, respectively)	The following unaffected by feeding at any dietary level: general condition, growth, food intake and efficiency, hematology, serum chemistry and urinalysis. No diarrhea, but water content of feces and amount of feces dry matter per 100 g of food consumed increased after feeding at dietary concentrations of 10% and 25%. Cecal weights, both filled and empty, increased only in 25% dietary group (males and females). Males of this group also showed slightly decreased relative weights of testes. Macroscopically, no test substance-related differences among the various groups.	⁸
Chronic Toxicity Studies						
Distarch Phosphate (maize starch cross-linked with sodium trimetaphosphate up to 0.04% introduced phosphorus and esterified with sodium tripolyphosphate up to a total content of 0.35% bound phosphorus)	30 male and 30 female rats (Wistar-derived)	104 wk	diet	0, 5, 10 and 30% (equivalent to 0, 2500, 5000 and 15,000 mg/kg bw/d, respectively)	No treatment-related effects noted on general appearance, behavior or mortality. Food intake, growth rate, and food efficiency in treated animals were comparable to controls. Hematology, clinical chemistry, and urinalysis revealed no consistent or dose-related differences between test and control groups. Relative organ weights comparable to those of controls, except for significantly decreased spleen weight in males and significantly increased spleen and kidney weights in females fed at 30% in diet. These changes not associated with any gross pathological findings. Cecal weights were not increased. When compared to controls, males fed 30% in diet showed slightly increased degree and incidence of focal hyperplasia of renal papillary and pelvic epithelium, accompanied by calcified patches in underlying tissue. Hyperplastic and calcified tissues often protruded into renal pelvis and were localized in papilla near junction of papillary and pelvic epithelium. This lesion was observed to a slight or moderate degree in males and females at most dietary levels, including controls, but was more pronounced and of higher occurrence in males at the highest dietary level. Histological examination did not reveal distinct test substance-related changes.	^{5,17}

Table 6. Repeated dose oral toxicity studies

Ingredient	Animals/Group	Study Duration	Vehicle	Dose/Concentration/Protocol	Results	Reference
Distarch Phosphate Acetate	25 female Sprague-Dawley rats	1-yr in weanling rats (experiment 1) and separate 9-mo study utilizing 9-mo-old rats (experiment 2)	diet	30% Distarch Phosphate Acetate (equivalent to 15,000 mg/kg bw/d) or 30% unmodified starch, used as a control. Concentrations of calcium, phosphorus, and magnesium in the diet were 1%, 0.8% and 0.15%, respectively.	Study focused on kidney lesions associated with dietary modified starches. In both experiments, no differences between treated and control animals with respect to the following: body weight, food consumption, urine volume, urine pH and crystal content, or fecal mineral content. At necropsy, cecal weight was significantly increased, but no other treatment-related effects on relative organ weights observed. No treatment-related histopathological effects observed in uterus or lower urinary tract, liver, parathyroid, cecum or ovaries in either experiment. Histopathological examination of kidney sections demonstrated presence of treatment-related pelvic nephrocalcinosis. Apparent correlation observed between increased incidence of pelvic nephrocalcinosis, increased accumulation of calcium in kidney, and increased urinary excretion of calcium. Residues of calcium in kidney tissue significantly higher in test animals than in control animals.	8,18
Distarch Phosphate Acetate (potato starch cross-linked with 0.02% phosphorus oxychloride and acetylated with 8% acetic anhydride; acetyl content of 2.33%)	30 male and 30 female rats (Wistar-derived)	104 wk	diet	0%, 5%, 10% and 30% (equal to 0, 2500, 5000 and 15,000 mg/kg bw/d, respectively)	No treatment-related effects on general appearance, behavior or mortality. Food intake, growth rate, and food efficiency in treated animals comparable to controls. Final body weight slightly reduced (~10% lower; significant, at least in males at 30% in diet). Hematology, clinical chemistry and urinalysis revealed no consistent or dose-related differences between test and control groups. Females had dose-related increase in relative adrenal weight (significant at 30% in diet). Dose-related increase in cecal weight in both sexes at 30% in diet, but only in males at 10% in diet. Cecal enlargement attributed to adaptive response (fermentation) to presence of indigestible material, rather than to a pathological response. All other organ weights showed no treatment-related changes. Only treatment-related effect observed histologically was kidney lesion, which occurred at higher incidence in high-dose males. Lesion consisted of suburothelial deposits of calcium, accompanied by focal hyperplasia of renal pelvis epithelium.	8,17
Hydroxypropyl Starch Phosphate	75 male and 75 female Swiss albino SPF mice	89 wk	diet	55% Hydroxypropyl Starch Phosphate (equivalent to 27,500 mg/kg bw/d) or control diet containing 55% pregelatinized potato starch	In wk 80, 10 mice/sex per group killed and necropsied. After 89 wk, all survivors killed and subjected to necropsy. Loose stools and slight diarrhea observed in 12% of males and 5% of females. In control group, these results slightly lower (males: 4; females: 3%). Loss of body weight prior to death observed in ~25% of male control animals; in other groups, at most 10% of males lost weight. Such differences between groups not observed in females. Death rate in groups quite normal for strain of mice used, except for fairly high mortality in males of control group between wk 39 and wk 65. Compared to controls, body weights in test group significantly decreased in males from wk 16 to 48, and in females from wk 40 onward. Water intake increased in males and females of test group (up to ~100% in wk 86). Hematocrit reduced in both sexes at wk 40, but not at wk 78. Clinical chemistry unaffected. In male mice, higher incidence of amorphous material in urine, and rate of turbid urine was higher. Urine sediment consisted of nearly 100% protein. Cecum weight of test animals, with or without contents, was statistically higher when compared to control group. Similar differences found for colon. Histopathological evaluation revealed increase in incidence of intratubular mineralization in the kidneys of test male and female mice	8,19

Table 7. Oral carcinogenicity studies

Ingredient	Animals/Group	Study Duration	Vehicle	Dose/Concentration	Results	Reference
Distarch Phosphate (maize starch 'white milo,' cross-linked with sodium trimetaphosphate up to 0.04% introduced phosphorus and esterified with sodium tripolyphosphate up to a total content of 0.35% bound phosphorus)	30 male and 30 female rats (Wistar-derived)	104 wk	diet	0%, 5%, 10% and 30% (equivalent to 0, 2500, 5000 and 15,000 mg/kg bw/d, respectively)	No indication of carcinogenicity in the following tissues/organs examined: lung, adrenals, thyroid, pituitary, mammary glands, skin/subcutis, abdomen, brain, thymus, forestomach, liver, pancreas, testes, ovaries, and uterus	^{8,17}
Distarch Phosphate Acetate (potato starch cross-linked with 0.02% phosphorus oxychloride and acetylated with 8% acetic anhydride; acetyl content of 2.33%)	30 male and 30 female rats (Wistar-derived)	104 wk	diet	0%, 5%, 10% and 30% (equivalent to 0, 2500, 5000 and 15,000 mg/kg bw/d, respectively)	No treatment-related effect observed on pattern of neoplasm development in the following tissues/organs: lung, adrenals, thyroid, pituitary, mammary glands, skin/subcutis, abdomen, brain, thymus, forestomach, liver, pancreas, testes, ovaries, and uterus	^{8,17}
Hydroxypropyl Starch Phosphate	75 male and 75 female Swiss albino SPF mice	89 wk	diet	55% (equivalent to 27,500 mg/kg bw/d). Control diet containing 55% pregelatinized potato starch	After 89 wk, all survivors killed and subjected to necropsy. No evidence of carcinogenicity in the following tissues/organs: lung, adrenals, thyroid, pituitary, mammary glands, skin/subcutis, abdomen, brain, thymus, liver, pancreas, ovaries, uterus, blood, mesenteric lymph nodes, axillary lymph nodes, subparotid lymph nodes, spleen, intestines, ear shell, kidneys, parathyroid, uterus/cervix, and seminal vesicles	^{8,19}

Table 8. Dermal irritation and sensitization studies

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
HUMAN					
Irritation					
Conditioner containing 2% Hydroxypropyl Starch Phosphate	tested as a 25% aqueous (aq.) solution (Hydroxypropyl Starch Phosphate effective concentration = 0.5%)	15 subjects (test article) 14 subjects (controls)	Single insult occlusive patch test (SIOPT). Patches were applied for 24 h. A different conditioner formulation served as reference control. Reactions were scored after patch removal, and a primary irritation index (PII) was calculated.	A PII of 0 was reported for the test article, and 0.03 for the reference control. It was concluded that there were no significant differences in irritation between the test material and the control.	²¹
Sensitization					
Eyeliner containing 7.181% Distarch Phosphate	applied neat	25 subjects	Maximization test evaluating sensitization potential. During induction, ~ 0.05 ml of aq. SLS (0.25%) applied for 24 h, under 15 mm occlusive patch to upper outer arm, volar forearm or the back. After 24 h, SLS patch removed and the test product (0.05 ml) was applied for 48 h to same site. (Induction patches remained in place for 72 h when placed over weekend.) This sequence repeated for a total of 5 induction exposures. After a 10-d non-treatment period, a previously untreated site was pre-treated with 5% aq. SLS for 1 h, after which an occlusive challenge patch was applied for 48 h. Reactions scored 15-30 min to 1 h after removal, and 24 h later.	There was no evidence of contact allergy in any of the subjects tested. It was concluded that the eyeliner did not possess a detectable contact-sensitizing potential, and thus, is not likely to cause contact sensitizing reactions under normal use conditions.	²⁰
Conditioner containing 2% Hydroxypropyl Starch Phosphate	0.2 ml tested as a 25% aq. solution (Hydroxypropyl Starch Phosphate effective concentration = 0.5%)	104 subjects	HRIPT evaluating sensitization potential. During induction, diluted product (0.2 ml) placed on an occlusive patch (2 cm x 2 cm), was applied to the infrascapular area of the back (either to right or left of midline), or to the upper arm. Induction phase consisted of nine 24-h applications (made on Mondays, Wednesdays, and Fridays) made over 3 consecutive weeks. After a 10-15 d non-treatment period, challenge patches were applied for 24 h to previously untreated sites. Reactions scored at 48 h and 72 h after patch removal.	During induction, definite erythema (readings 3 and 4) and a minimal doubtful response (readings 5-9) was reported for one subject. No other reactions were reported during induction, and none were observed for any of the subjects at challenge. Under the conditions employed in this study, there was no evidence of sensitization to the diluted product.	²²

Abbreviations: HRIPT – human repeated insult patch test; SIOPT – single insult occlusive patch test; SLS – sodium lauryl sulfate

REFERENCES

1. Nikitakis J, Kowcz A, (eds) *International Cosmetic Ingredient Dictionary and Handbook*, Online Version (wINCI). <http://webdictionary.personalcarecouncil.org/jsp/Home.jsp>. 2020. Accessed: March 11, 2020.
2. Andersen FA (ed). Amended Final Report on the Safety Assessment of Oryza Sativa (Rice) Bran Oil, Oryza Sativa (Rice) Germ Oil, Rice Bran Acid, Oryza Sativa (Rice) Bran Wax, Hydrogenated Rice Bran Wax, Oryza Sativa (Rice) Bran Extract, Oryza Sativa (Rice) Extract, Oryza Sativa (Rice) Germ Powder, Oryza Sativa (Rice) Starch, Oryza Sativa (Rice) Bran, Hydrolyzed Rice Bran Extract Hydrolyzed Rice Bran Protein, Hydrolyzed Rice Extract, and Hydrolyzed Rice Protein. *Int J Toxicol* 2006;25(S2):91-120.
3. Andersen FA, Bergfeld WF, Belsito DV, et al. Final report of the safety assessment of cosmetic ingredients derived from Zea mays (corn). *Int J Toxicol*. 2011;30(S1):17S-39S.
4. Johnson W Jr, Heldreth B, Bergfeld WF, et al. 2015. Final report of the safety assessment of polysaccharide gums as used in cosmetic. Available on the CIR website. (<https://www.cir-safety.org/ingredients>)
5. World Health Organization (WHO), Joint FAO/WHO Expert Committee on Food Additives. Toxicological evaluation of some food additives including anticaking agents, antimicrobials, antioxidants, emulsifiers and thickening agents. WHO Food Additives Series No. 5. <http://www.inchem.org/documents/jecfa/jecmono/v05je75.htm>. 1974. Accessed: 2/3/2021.
6. World Health Organization (WHO). Joint FAO/WHO Expert Committee on Food Additives, 82nd meeting. Compendium of Food Additive Specifications. <http://www.fao.org/3/a-i6413e.pdf#page=39%22%3E>. 2016. Accessed: 2/2/2021.
7. World Health Organization (WHO), Joint FAO/WHO Expert Committee on Food Additives. Residue monograph; Hydroxypropyl Distarch Phosphate (Tentative). <http://www.fao.org/3/a-bt056e.pdf>. 2016. Accessed: 2/2/2021.
8. Mortensen A, Aguilar F, Crebelli R, et al. Re-evaluation of oxidised starch (E 1404), monostarch phosphate (E 1410), distarch phosphate (E 1412), phosphated distarch phosphate (E 1413), acetylated distarch phosphate (E 1414), acetylated starch (E 1420), acetylated distarch adipate (E 1422), hydroxypropyl starch (E 1440), hydroxypropyl distarch phosphate (E 1442), starch sodium octenyl succinate (E 1450), acetylated oxidised starch (E 1451) and starch aluminium octenyl succinate (E 1452) as food additives. *EFSA J*. 2017;15(10):e04911.
9. United States Pharmacopeial Convention. *Food Chemicals Codex*. 10th ed. Rockville, MD: 2016.
10. National Library of Medicine (NLM), ChemIDplus. Starch (RN 9005-25-8). <https://chem.nlm.nih.gov/chemidplus/name/starch>. 2022. Accessed: 1/18/2022.
11. Arnal G, Cockburn DW, Brumer H, Koropatkin NM. Structural basis for the flexible recognition of α -glucan substrates by *Bacteroides thetaiotaomicron* SusG. *Protein Sci*. 2018 27(6):1093-1101.
12. U.S. Food and Drug Administration Center for Food Safety & Applied Nutrition (CFSAN). 2022. Voluntary Cosmetic Registration Program - Frequency of Use of Cosmetic Ingredients. Obtained under the Freedom of Information Act from CFSAN; requested as "Frequency of Use Data" January 4, 2022; received January 11, 2022.
13. Personal Care Products Council (Council). 2021. Concentration of use by FDA product category: Starch Phosphates. Unpublished data submitted by the Personal Care Products Council on January 6, 2021.
14. European Commission. CosIng database; following Cosmetic Regulation No. 1223/2009. <http://ec.europa.eu/growth/tools-databases/cosing/>. Last Updated 2020. Accessed 2/1/2021.
15. National Library of Medicine, PubChem. Starch and Sucrose Metabolism (Pathway). <https://pubchem.ncbi.nlm.nih.gov/pathway/PathBank:SMP0000058>. 2022. Accessed: 1/18/2022.
16. Whistler RL, Belfort AM. Nutritional value of chemically modified corn starches. *Science*. 1961;133(3464):1599-1600.
17. de Groot AP, Til HP, Ferron VJ, Van der Meullen HCD, Williams MI. Two-year feeding and multigeneration studies in rats on five chemically modified starches. *Food Cosmet Toxicol*. 1974;12(5-6):651-663.

18. Hodgkinson A, Davis D, Fourman J, Robertson WG, Roe FJ. A comparison of the effects of lactose and of two chemically modified waxy maize starches on mineral metabolism in the rat. *Food Chem Toxicol.* 1982;20(4):371-382.
19. Til HP, Feron VJ, Immel HR, Vogel WF. Chronic (89-week) feeding study with hydroxypropyl distarch phosphate, starch acetate, lactose and sodium alginate in mice. *Food Chem Toxicol.* 1986;24(8):825-834.
20. Anonymous. 2004. An evaluation of the contact-sensitizing potential of a topical coded product in human skin by means of the maximization assay (eyeliner containing 7.181% Distarch Phosphate. Unpublished data submitted by the Personal Care Products Council on May 10, 2021.
21. Anonymous. 2018. Clinical evaluation report: Human patch test (conditioner contains 2% Hydroxypropyl Starch Phosphate). Unpublished data submitted by the Personal Care Products Council on May 10, 2021.
22. Anonymous. 2019. Repeated insult patch test (conditioner contains 2% Hydroxypropyl Starch Phosphate). Unpublished data submitted by the Personal Care Products Council on May 10, 2021.